Heather R. Johnson

To explore mortality rates, the researchers who conducted the current study compared the mortality rate in US Medicare patients diagnosed with Parkinson disease who used either Pimavanserin or atypical antipsychotics.

Researchers investigated whether high-potency cannabis may be associated with a higher risk of psychosis and cannabis use disorder compared with lower-potency products.

A group of researchers explored whether individuals who experienced ongoing discrimination had a higher risk for depression.

Researchers conducted a study of adults with dual diagnoses of psychiatric and substance use disorders which was published in Psychiatry Research.

Compared with its use for chronic pain, reliable evidence to support the use of cannabis to treat anxiety is lacking and available data are “conflicting.” To bring clarity to the issue, researchers conducted a retrospective database study of Canadian medical cannabis patients.

Researchers have developed a system of quantitative EEG analysis which delivers an EEG phenotype associated with depression or anxiety that is customizable to each patient.

The study authors searched several databases to find correlations between tobacco smoking and COVID-19 during the pre-vaccination phase of the pandemic.

The researchers analyzed past-year medication for opioid use disorder in individuals diagnosed with opioid use disorder who received some type of treatment.

A population-based cohort study in the US examined the data from over 2 million Medicaid patients to ascertain if there were any differences in the incidence and timing for diagnosis of neurodevelopmental disorders in publicly vs privately insured children.

Depressive symptoms and sleep disorders, including insomnia, hypersomnia, and disrupted breathing, are considered heart disease risk factors. Other studies have linked sleep disorders and depression. This study analyzes heart disease risk in people with both sleep disorders and depression.